TRAIL-mediated armA upregulation enhances the drug resistance of Klebsiella pneumoniae by activating the PI3K/AKT/mTOR signaling pathway.

IF 1.6 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
American journal of translational research Pub Date : 2025-08-15 eCollection Date: 2025-01-01 DOI:10.62347/QVUY9908
Bu Wang, Wei Zhang, Jianhua Liu, Hongxia Zhang, Maochen Li, Xiaocui Peng, Zhihua Zhang, Ning Song
{"title":"TRAIL-mediated armA upregulation enhances the drug resistance of <i>Klebsiella pneumoniae</i> by activating the PI3K/AKT/mTOR signaling pathway.","authors":"Bu Wang, Wei Zhang, Jianhua Liu, Hongxia Zhang, Maochen Li, Xiaocui Peng, Zhihua Zhang, Ning Song","doi":"10.62347/QVUY9908","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the roles and mechanisms of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in the drug resistance of <i>Klebsiella pneumoniae</i>, focusing on its regulation of the aminoglycoside resistance methylase (armA) and the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway.</p><p><strong>Methods: </strong>A549 cells were infected with drug-resistant <i>Klebsiella pneumoniae</i> and treated with meropenem. TRAIL overexpression and knockdown were performed using plasmids and small interfering RNA, respectively. Cell viability, apoptosis, and the levels of inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) were assessed. The mRNA expression of armA was examined using reverse transcription quantitative polymerase chain reaction (RT-qPCR). The expression of key proteins in the PI3K/AKT/mTOR pathway was evaluated using western blots.</p><p><strong>Results: </strong>Drug-resistant <i>Klebsiella pneumoniae</i> infection reduced A549 cell viability, promoted apoptosis, and increased TNF-α, IL-6, and IL-1β levels. Meropenem treatment failed to reverse these effects, confirming the drug resistance. TRAIL overexpression exacerbated <i>Klebsiella pneumoniae</i> infection-induced viability inhibition, apoptosis, and inflammation, suggesting that TRAIL enhances the drug resistance of <i>Klebsiella pneumoniae</i>. In contrast, TRAIL knockdown showed the opposite results. TRAIL overexpression upregulated armA expression and activated the PI3K/AKT/mTOR pathway, but armA inhibition reversed TRAIL-mediated drug resistance and PI3K/AKT/mTOR activation.</p><p><strong>Conclusion: </strong>TRAIL-mediated armA upregulation enhanced the drug resistance of <i>Klebsiella pneumoniae</i> by activating the PI3K/AKT/mTOR signaling pathway. These findings provide new insight into the drug resistance mechanisms of <i>Klebsiella pneumoniae</i>.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 8","pages":"6103-6112"},"PeriodicalIF":1.6000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432726/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of translational research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/QVUY9908","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aimed to investigate the roles and mechanisms of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in the drug resistance of Klebsiella pneumoniae, focusing on its regulation of the aminoglycoside resistance methylase (armA) and the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway.

Methods: A549 cells were infected with drug-resistant Klebsiella pneumoniae and treated with meropenem. TRAIL overexpression and knockdown were performed using plasmids and small interfering RNA, respectively. Cell viability, apoptosis, and the levels of inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) were assessed. The mRNA expression of armA was examined using reverse transcription quantitative polymerase chain reaction (RT-qPCR). The expression of key proteins in the PI3K/AKT/mTOR pathway was evaluated using western blots.

Results: Drug-resistant Klebsiella pneumoniae infection reduced A549 cell viability, promoted apoptosis, and increased TNF-α, IL-6, and IL-1β levels. Meropenem treatment failed to reverse these effects, confirming the drug resistance. TRAIL overexpression exacerbated Klebsiella pneumoniae infection-induced viability inhibition, apoptosis, and inflammation, suggesting that TRAIL enhances the drug resistance of Klebsiella pneumoniae. In contrast, TRAIL knockdown showed the opposite results. TRAIL overexpression upregulated armA expression and activated the PI3K/AKT/mTOR pathway, but armA inhibition reversed TRAIL-mediated drug resistance and PI3K/AKT/mTOR activation.

Conclusion: TRAIL-mediated armA upregulation enhanced the drug resistance of Klebsiella pneumoniae by activating the PI3K/AKT/mTOR signaling pathway. These findings provide new insight into the drug resistance mechanisms of Klebsiella pneumoniae.

trail介导的armA上调通过激活PI3K/AKT/mTOR信号通路增强肺炎克雷伯菌的耐药性。
目的:探讨肿瘤坏死因子相关凋亡诱导配体(TRAIL)在肺炎克雷伯菌耐药中的作用及机制,重点研究TRAIL对氨基糖苷耐药甲基化酶(armA)和磷脂酰肌醇-3激酶(PI3K)/蛋白激酶B (AKT)/哺乳动物雷帕霉素靶蛋白(mTOR)信号通路的调控作用。方法:用耐药肺炎克雷伯菌感染A549细胞,并用美罗培南治疗。利用质粒和小干扰RNA分别进行TRAIL过表达和敲低。评估细胞活力、凋亡和炎性细胞因子水平,包括肿瘤坏死因子-α (TNF-α)、白细胞介素-6 (IL-6)和白细胞介素-1β (IL-1β)。采用逆转录定量聚合酶链反应(RT-qPCR)检测armA mRNA表达。western blots检测PI3K/AKT/mTOR通路关键蛋白的表达。结果:耐药肺炎克雷伯菌感染降低A549细胞活力,促进细胞凋亡,升高TNF-α、IL-6和IL-1β水平。美罗培南治疗未能逆转这些影响,证实了耐药性。TRAIL过表达加重了肺炎克雷伯菌感染诱导的活力抑制、细胞凋亡和炎症,提示TRAIL增强了肺炎克雷伯菌的耐药性。相反,TRAIL敲低则显示相反的结果。TRAIL过表达上调了armA表达,激活了PI3K/AKT/mTOR通路,但armA抑制逆转了TRAIL介导的耐药和PI3K/AKT/mTOR活化。结论:trail介导的armA上调通过激活PI3K/AKT/mTOR信号通路增强肺炎克雷伯菌的耐药性。这些发现为肺炎克雷伯菌的耐药机制提供了新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American journal of translational research
American journal of translational research ONCOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
自引率
0.00%
发文量
552
期刊介绍: Information not localized
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信